Vol 70, No 6 (2019)
Review paper
Published online: 2019-12-20

open access

Page views 5266
Article views/downloads 4155
Get Citation

Connect on Social Media

Connect on Social Media

Endocrine diseases as causes of secondary hyperlipidemia

Łukasz Bułdak1, Bogdan Marek2, Dariusz Kajdaniuk2, Agata Urbanek3, Szymon Janyga3, Aleksandra Bołdys1, Marcin Basiak1, Mateusz Maligłówka1, Bogusław Okopień1
Pubmed: 31891414
Endokrynol Pol 2019;70(6):511-519.


Cardiovascular diseases are among the leading causes of increased morbidity and mortality in developed and developing countries. One of the most important risk factors responsible for atherosclerosis and subsequent cardiovascular diseases is hyperlipidaemia. Currently, hyperlipidaemias are divided into several clinical entities. The greatest risk is associated with hypercholesterolaemia. As a result, modern guidelines for the treatment and prevention of atherosclerosis focus predominantly on the reduction of LDL-cholesterol. Hypertriglyceridaemia and atherogenic dyslipidaemia, which are responsible for a less significant increase in the cardiovascular risk, are nowadays secondary targets of the treatment.

During the work-up for hyperlipidaemia one of the essential actions is the exclusion of secondary causes of the lipid abnormalities. Those include, among others, endocrine diseases, diabetes, drugs, nephrotic syndrome, and pregnancy. Data regarding the impact of endocrine disease and diabetes on the lipid profile are scattered. In this review, the authors aimed to perform a thorough analysis of the available publications regarding the topic and the preparation of a comprehensive review dealing with the incidence, clinical features, and the therapy of hyperlipidaemias in patients with endocrine disease. 

Article available in PDF format

View PDF Download PDF file


  1. Catapano AL, Graham I, De Backer G, et al. ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016; 37(39): 2999–3058.
  2. Vodnala D, Rubenfire M, Brook RD. Secondary causes of dyslipidemia. Am J Cardiol. 2012; 110(6): 823–825.
  3. O'Keefe JH, Cordain L, Harris WH, et al. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004; 43(11): 2142–2146.
  4. Carr RA, Rejowski BJ, Cote GA, et al. Systematic review of hypertriglyceridemia-induced acute pancreatitis: A more virulent etiology? Pancreatology. 2016; 16(4): 469–476.
  5. Fredrickson DS, LEES RS. A system for phenotyping hyperlipoproteinemia. Circulation. 1965; 31: 321–327.
  6. Hirano T. Pathophysiology of Diabetic Dyslipidemia. J Atheroscler Thromb. 2018; 25(9): 771–782.
  7. Nigam PK. Serum Lipid Profile: Fasting or Non-fasting? Indian J Clin Biochem. 2011; 26(1): 96–97.
  8. Pearce EN. Update in lipid alterations in subclinical hypothyroidism. J Clin Endocrinol Metab. 2012; 97(2): 326–333.
  9. Asvold BO, Vatten LJ, Nilsen TIL, et al. The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study. Eur J Endocrinol. 2007; 156(2): 181–186.
  10. Cojić M, Cvejanov-Kezunović L. Subclinical Hypothyroidism — Whether and When To Start Treatment? Open Access Maced J Med Sci. 2017; 5(7): 1042–1046.
  11. Ineck BA, Ng TMH. Effects of subclinical hypothyroidism and its treatment on serum lipids. Ann Pharmacother. 2003; 37(5): 725–730.
  12. Tokinaga K, Oeda T, Suzuki Y, et al. HMG-CoA reductase inhibitors (statins) might cause high elevations of creatine phosphokinase (CK) in patients with unnoticed hypothyroidism. Endocr J. 2006; 53(3): 401–405.
  13. Andrikoula M, Avades T. Hypolipidaemia is not always indicating liver dysfunction. A review of primary and secondary high density lipoprotein and low density lipoprotein deficiencies. Minerva Med. 2006; 97(6): 487–494.
  14. Patti AM, Giglio RV, Papanas N, et al. Future perspectives of the pharmacological management of diabetic dyslipidemia. Expert Rev Clin Pharmacol. 2019; 12(2): 129–143.
  15. Feher M, Greener M, Munro N. Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2013; 6: 11–15.
  16. Pang J, Chan DC, Watts GF. Origin and therapy for hypertriglyceridaemia in type 2 diabetes. World J Diabetes. 2014; 5(2): 165–175.
  17. Katakami N. Mechanism of Development of Atherosclerosis and Cardiovascular Disease in Diabetes Mellitus. J Atheroscler Thromb. 2018; 25(1): 27–39.
  18. Okopień B, Buldak L, Bołdys A. Fibrates in the management of atherogenic dyslipidemia. Expert Rev Cardiovasc Ther. 2017; 15(12): 913–921.
  19. Lichtenstein AH, Ausman LM, Jalbert SM, et al. Efficacy of a Therapeutic Lifestyle Change/Step 2 diet in moderately hypercholesterolemic middle-aged and elderly female and male subjects. J Lipid Res. 2002; 43(2): 264–273.
  20. Miller M, Stone NJ, Ballantyne C, et al. American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011; 123(20): 2292–2333.
  21. Greenman Y. Management of dyslipidemia in Cushing's syndrome. Neuroendocrinology. 2010; 92 Suppl 1: 91–95.
  22. Lopez D, Luque-Fernandez MA, Steele A, et al. "Nonfunctional" Adrenal Tumors and the Risk for Incident Diabetes and Cardiovascular Outcomes: A Cohort Study. Ann Intern Med. 2016; 165(8): 533–542.
  23. Tauchmanovà L, Rossi R, Biondi B, et al. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab. 2002; 87(11): 4872–4878.
  24. Anagnostis P, Athyros VG, Tziomalos K, et al. Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab. 2009; 94(8): 2692–2701.
  25. Meikle AW, Findling J, Kushnir MM, et al. Pseudo-Cushing syndrome caused by fenofibrate interference with urinary cortisol assayed by high-performance liquid chromatography. J Clin Endocrinol Metab. 2003; 88(8): 3521–3524.
  26. Perić B, Kruljac I, Šundalić S, et al. Obesity and hypercholesterolemia in patients with prolactinomas: Could DHEA-S and growth hormone be the missing link? Endocr Res. 2016; 41(3): 200–206.
  27. Ling C, Svensson L, Odén B, et al. Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab. 2003; 88(4): 1804–1808.
  28. Krysiak R, Marek B, Okopień B. Cardiometabolic risk factors in young women with macroprolactinaemia. Endokrynol Pol. 2019; 70(4): 336–341.
  29. Berinder K, Nyström T, Höybye C, et al. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary. 2011; 14(3): 199–207.
  30. Krysiak R, Szkróbka W, Okopień B. Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia. Pharmacol Rep. 2019; 71(1): 61–66.
  31. Woodmansee WW, Gordon MB, Molitch ME, et al. Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis. Endocrine. 2018; 61(1): 105–117.
  32. Tsuchiya H, Onishi T, Mogami H, et al. Lipid metabolism in acromegalic patients before and after selective pituitary adenomectomy. Endocrinol Jpn. 1990; 37(6): 797–807.
  33. Ioaniţiu D, Bartoc R, Ispas I, et al. The dyslipemic syndrome in acromegaly. Endocrinologie. 1982; 20(1): 25–36.
  34. Nikkilä EA, Pelkonen R. Serum lipids in acromegaly. Metabolism. 1975; 24(7): 829–838.
  35. Takeda R, Tatami R, Ueda K, et al. Secondary type V hyperlipoproteinemia in an acromegalic patient without overt diabetes. Endokrinologie. 1982; 79(1): 140–148.
  36. Cansu GB, Yılmaz N, Yanıkoğlu A, et al. Assessment of diastolic dysfunction, arterial stiffness, and carotid intima-media thickness in patients with acromegaly. Endocr Pract. 2017; 23(5): 536–545.
  37. Golkowski F, Krzentowska-Korek A, Baldys-Waligorska A, et al. Goiter, cardiovascular and metabolic disorders in patients with acromegaly. Endocr Regul. 2011; 45(4): 191–197.
  38. Tsuchiya H, Onishi T, Mogami H, et al. Lipid metabolism in acromegalic patients before and after selective pituitary adenomectomy. Endocrinol Jpn. 1990; 37(6): 797–807.
  39. Takeda R, Tatami R, Ueda K, et al. The incidence and pathogenesis of hyperlipidaemia in 16 consecutive acromegalic patients. Acta Endocrinol (Copenh). 1982; 100(3): 358–362.
  40. Takeda R, Tatami R, Ueda K, et al. Secondary type V hyperlipoproteinemia in an acromegalic patient without overt diabetes. Endokrinologie. 1982; 79(1): 140–148.
  41. Caron PJ, Petersenn S, Houchard A, et al. PRIMARYS Study Group. Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naïve patients with acromegaly: data from the PRIMARYS study. Clin Endocrinol (Oxf). 2017; 86(4): 541–551.
  42. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011; 305(24): 2556–2564.
  43. Lewiński A, Smyczyńska J, Stawerska R, et al. National Program of Severe Growth Hormone Deficiency Treatment in Adults and Adolescents after Completion of Growth Promoting Therapy. Endokrynol Pol. 2018; 69(5): 468–524.
  44. van der Klaauw AA, Biermasz NR, Feskens EJM, et al. The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. Eur J Endocrinol. 2007; 156(4): 455–462.
  45. Itoh E, Hizuka N, Fukuda I, et al. Metabolic disorders in adult growth hormone deficiency: A study of 110 patients at a single institute in Japan. Endocr J. 2006; 53(4): 539–545.
  46. Kohno H, Tanaka T, Fujieda K, et al. Favorable Impacts of Growth Hormone (GH) Replacement Therapy on Atherogenic Risks in Japanese Children with GH Deficiency. Clin Pediatr Endocrinol. 2012; 21(2): 15–20.
  47. Shimatsu A, Tai S, Imori M, et al. Efficacy and safety of growth hormone replacement therapy in Japanese adults with growth hormone deficiency: a post-marketing observational study. Endocr J. 2013; 60(10): 1131–1144.
  48. Norrman LL, Johannsson G, Sunnerhagen KS, et al. Baseline characteristics and the effects of two years of growth hormone (GH) replacement therapy in adults with GH deficiency previously treated for acromegaly. J Clin Endocrinol Metab. 2008; 93(7): 2531–2538.
  49. Claessen KM, Appelman-Dijkstra NM, Pereira AM, et al. Abnormal metabolic phenotype in middle-aged GH-deficient adults despite long-term recombinant human GH replacement. Eur J Endocrinol. 2014; 170(2): 263–272.
  50. Andrikoula M, Sertedaki A, Andrikoula S, et al. PROP-1 gene mutations in a 63-year-old woman presenting with osteoporosis and hyperlipidaemia. Hormones (Athens). 2013; 12(1): 128–134.
  51. Ishibashi S, Murase T, Yamada N, et al. Hyperlipidaemia in patients with hypopituitarism. Acta Endocrinol (Copenh). 1985; 110(4): 456–460.
  52. Dutkowska A, Konieczna A, Breska-Kruszewska J, et al. [Recomendations on non-pharmacological interventions in women with PCOS to reduce body weight and improve metabolic disorders [Zalecenia dotyczące postępowania niefarmakologicznego u kobiet z PCOS celem zmniejszenia masy ciała i poprawy zaburzeń metabolicznych]. Endokrynol Pol. 2019; 70(2): 198–212.
  53. Milewicz A, Kudła M, Spaczyński RZ, et al. The polycystic ovary syndrome: a position statement from the Polish Society of Endocrinology, the Polish Society of Gynaecologists and Obstetricians, and the Polish Society of Gynaecological Endocrinology. Endokrynol Pol. 2018; 69(4).
  54. Puurunen J, Piltonen T, Puukka K, et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2013; 98(12): 4798–4807.
  55. Wang Q, Würtz P, Auro K, et al. Effects of hormonal contraception on systemic metabolism: cross-sectional and longitudinal evidence. Int J Epidemiol. 2016; 45(5): 1445–1457.
  56. Stumpf MA, Kluthcovsky AC, Okamoto JM, et al. Acute pancreatitis secondary to oral contraceptive-induced hypertriglyceridemia: a case report. Gynecol Endocrinol. 2018; 34(11): 930–932.
  57. Basaria S. Male hypogonadism. Lancet. 2014; 383(9924): 1250–1263.
  58. Dimitriadis GK, Randeva HS, Aftab S, et al. Metabolic phenotype of male obesity-related secondary hypogonadism pre-replacement and post-replacement therapy with intra-muscular testosterone undecanoate therapy. Endocrine. 2018; 60(1): 175–184.
  59. Mohler ER, Ellenberg SS, Lewis CE, et al. The Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials. J Clin Endocrinol Metab. 2018; 103(2): 681–688.
  60. Zhang J, Yang B, Xiao W, et al. Effects of testosterone supplement treatment in hypogonadal adult males with T2DM: a meta-analysis and systematic review. World J Urol. 2018; 36(8): 1315–1326.
  61. Rezanezhad B, Borgquist R, Willenheimer R, et al. Association between serum levels of testosterone and biomarkers of subclinical atherosclerosis. Aging Male. 2018; 21(3): 182–186.
  62. Zhang KS, Zhao MJ, An Q, et al. Effects of testosterone supplementation therapy on lipid metabolism in hypogonadal men with T2DM: a meta-analysis of randomized controlled trials. Andrology. 2018; 6(1): 37–46.
  63. Dos Santos Mota MP, Gomes Moura IC, Marinho RM, et al. Evaluation of Cardiovascular Risk in Climacteric Women: A Cross-Sectional Study. J Midlife Health. 2018; 9(3): 123–129.
  64. Welty F. Preventing clinically evident coronary heart disease in the postmenopausal woman. Menopause. 2004; 11(4): 484–494.
  65. Miller VM, Naftolin F, Asthana S, et al. The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? Menopause. 2019 [Epub ahead of print]; 26(9): 1071–1084.
  66. Han D, Trooskin S, Wang X. Prevalence of cardiovascular risk factors in male and female patients with primary hyperparathyroidism. J Endocrinol Invest. 2012; 35(6): 548–552.
  67. Lacour B, Roullet JB, Liagre AM, et al. Serum lipoprotein disturbances in primary and secondary hyperparathyroidism and effects of parathyroidectomy. Am J Kidney Dis. 1986; 8(6): 422–429.
  68. Godang K, Lundstam K, Mollerup C, et al. The effect of surgery on fat mass, lipid and glucose metabolism in mild primary hyperparathyroidism. Endocr Connect. 2018; 7(8): 941–948.
  69. Murase T, Yamada N, Ohsawa N, et al. Decline of postheparin plasma lipoprotein lipase in acromegalic patients. Metabolism. 1980; 29(7): 666–672.
  70. Werumeus Buning J, Dimova LG, Perton FG, et al. Downregulation of cholesteryl ester transfer protein by glucocorticoids: a randomised study on HDL. Eur J Clin Invest. 2017; 47(7): 494–503.
  71. Dullaart RPF, De Vries R, Scheek L, et al. Type 2 diabetes mellitus is associated with differential effects on plasma cholesteryl ester transfer protein and phospholipid transfer protein activities and concentrations. Scand J Clin Lab Invest. 2004; 64(3): 205–215.
  72. Duvillard L, Florentin E, Lizard G, et al. Cell surface expression of LDL receptor is decreased in type 2 diabetic patients and is normalized by insulin therapy. Diabetes Care. 2003; 26(5): 1540–1544.
  73. Arnaldi G, Scandali VM, Trementino L, et al. Pathophysiology of dyslipidemia in Cushing's syndrome. Neuroendocrinology. 2010; 92(Suppl 1): 86–90.
  74. Sinha RA, Singh BK, Yen PM. Direct effects of thyroid hormones on hepatic lipid metabolism. Nat Rev Endocrinol. 2018; 14(5): 259–269.
  75. Twickler TB, Cramer MJM, Dallinga-Thie GM, et al. Adult-onset growth hormone deficiency: Relation of postprandial dyslipidemia to premature atherosclerosis. J Clin Endocrinol Metab. 2003; 88(6): 2479–2488.
  76. Valdemarsson S, Hansson P, Hedner P, et al. Relations between thyroid function, hepatic and lipoprotein lipase activities, and plasma lipoprotein concentrations. Acta Endocrinol (Copenh). 1983; 104(1): 50–56.